Exenatide tests well against competing therapy

Researchers say that exenatide proved as effective as NovoNordisk's NovoMix 30 in improving blood sugar levels in patients with type 2 diabetes who do not respond to two standard therapies. Eighteen percent of the patients given exenatide--developed by Eli Lilly and Amylin Pharmaceuticals--achieved recommended blood sugar levels compared to nine percent in the NovoMix 30 group. And the exenatide patients lost weight on average, compared to a weight gain among those taking insulin.

- check out the report from the AP on Exenatide

PLUS: Merck released new data that demonstrates the ability of Januvia in combination with another therapy to lower blood sugars to a reasonable level in patients with type 2 diabetes. Merck has filed for FDA approval of Januvia. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.